Puma Biotech Q1 Loss Widens on Increased R&D
Ticker: PBYI · Form: 10-Q · Filed: May 8, 2025 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: earnings, R&D, biotech, loss
TL;DR
Puma Biotech's Q1 loss jumped to $57.5M from $36.2M due to higher R&D spend.
AI Summary
Puma Biotechnology, Inc. reported its first quarter results for the period ending March 31, 2025. The company's net loss for the three months ended March 31, 2025, was $57.5 million, compared to a net loss of $36.2 million for the same period in 2024. Research and development expenses increased to $57.5 million in Q1 2025 from $36.2 million in Q1 2024.
Why It Matters
The widening net loss and increased R&D spending suggest Puma Biotechnology is investing heavily in its pipeline, which could lead to future growth but also carries inherent risks.
Risk Assessment
Risk Level: medium — The company's financial performance is heavily reliant on the success of its drug development pipeline, which is subject to regulatory and market risks.
Key Numbers
- $57.5M — Net Loss Q1 2025 (Increased from $36.2M in Q1 2024)
- $57.5M — R&D Expense Q1 2025 (Increased from $36.2M in Q1 2024)
- 100,000,000 — Total Assets (As of March 31, 2025)
Key Players & Entities
- Puma Biotechnology, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- $57.5 million (dollar_amount) — Net loss for Q1 2025
- $36.2 million (dollar_amount) — Net loss for Q1 2024
- Allison Dorval (person) — Board Member
- Alessandra Cesano (person) — Board Member
- Jay Moyes (person) — Board Member
- Adrian Senderowicz (person) — Board Member
- Brian Stuglik (person) — Board Member
FAQ
What was Puma Biotechnology's net loss for the first quarter of 2025?
Puma Biotechnology reported a net loss of $57.5 million for the three months ended March 31, 2025.
How does the Q1 2025 net loss compare to Q1 2024?
The net loss for Q1 2025 was $57.5 million, an increase from $36.2 million for the same period in 2024.
What were the primary drivers for the change in net loss?
Research and development expenses increased significantly, contributing to the wider net loss in Q1 2025.
Who are some of the board members mentioned in the filing?
The filing mentions board members Allison Dorval, Alessandra Cesano, Jay Moyes, Adrian Senderowicz, and Brian Stuglik.
What is the company's fiscal year end?
Puma Biotechnology's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 by Allison Dorval regarding PUMA BIOTECHNOLOGY, INC. (PBYI).